The research, published in the prestigious Journal of Biological Chemistry, aimed to study in depth the already known effects of lessening the symptoms and stopping the advance of multiple sclerosis that cannabinoids have, while developing a drug that would not have the psychoactive effects of the marijuana plant (Cannabis sativa).
To achieve this, the scientists have focused their study on the role of the cannabinoids receptor CB2, present both in the immune system as well as in the defence-cells of the nervous system (microglial cells).
Multiple sclerosis is a neurodegenerative disease whose causes are not yet fully understood. It is known that the disease is produced by an autoimmune response where the defence-cells in the organism attack and destroy the nerve cells of the organism generating symptoms such as stiffness, twitching, progressive paralysis, etc.
The researchers managed by Professor Ismael Galve from the UCM, founded their conclusions on the role of the cannabinoids receptors in Experimental autoimmune encephalomyelitis, a disease that reproduces some of the proceses and symptoms of multiple sclerosis. In the study it has been tested that administering a drug that activates receptor CB2 (but not CB1, responsible for the psicoactive effects), the sysmptopms of the disease lessen and a reduction of 50% in nerve cell loss was perceived.
This research has introduced yet another novelty: The stimulation of the CB2 receptor not only reduces the excesive activation of brain cells in charge of the defence of the central nervous system, but it allso reduces the supply of new defence-cells that travelling throught the blood stream from bone marrow, would act as reinforcements for the defence-cells of the central nervous system.
According to Ismael Galve, the results are important because the drug is capable of acting in an already sick animal, reducing the symptoms and the brain cell loss. The obtained results, along with other predecessors confirm the role of endogenous cannabinoids in the origin of experimental autoimmune encephalomyelitis and its possible application to multiple esclerosis. Therefore the role of the CB2 receptor in the regulation and neuro-inmune response supports the research currently being carried out on the possible use of cannabinoid drugs in the treatment of neurodegenerative diseases.
The research has been carried out by the department of biochemistry and molecular biology of the Complutense University of Madrid, in collaboration with the Neuroscience research Institute of Lyon in France and the pharmaceutical company Pharmos.
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy